These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ghosh SS; Swerdlow RH; Miller SW; Sheeman B; Parker WD; Davis RE Ann N Y Acad Sci; 1999; 893():176-91. PubMed ID: 10672237 [TBL] [Abstract][Full Text] [Related]
9. Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Swerdlow RH; Parks JK; Cassarino DS; Shilling AT; Bennett JP; Harrison MB; Parker WD Biochem Biophys Res Commun; 1999 Aug; 261(3):701-4. PubMed ID: 10441489 [TBL] [Abstract][Full Text] [Related]
10. Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture. Trimmer PA; Keeney PM; Borland MK; Simon FA; Almeida J; Swerdlow RH; Parks JP; Parker WD; Bennett JP Neurobiol Dis; 2004 Feb; 15(1):29-39. PubMed ID: 14751768 [TBL] [Abstract][Full Text] [Related]
11. The A8296G mtDNA mutation associated with several mitochondrial diseases does not cause mitochondrial dysfunction in cybrid cell lines. Bornstein B; Mas JA; Fernández-Moreno MA; Campos Y; Martín MA; del Hoyo P; Rubio JC; Arenas J; Garesse R Hum Mutat; 2002 Mar; 19(3):234-9. PubMed ID: 11857739 [TBL] [Abstract][Full Text] [Related]
12. Crosstalk from non-cancerous mitochondria can inhibit tumor properties of metastatic cells by suppressing oncogenic pathways. Kaipparettu BA; Ma Y; Park JH; Lee TL; Zhang Y; Yotnda P; Creighton CJ; Chan WY; Wong LJ PLoS One; 2013; 8(5):e61747. PubMed ID: 23671572 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of mtDNA depleted and repleted NT2 cell lines. Binder DR; Dunn WH; Swerdlow RH Mitochondrion; 2005 Aug; 5(4):255-65. PubMed ID: 16050988 [TBL] [Abstract][Full Text] [Related]
14. An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model. Cavaliere A; Marchet S; Di Meo I; Tiranti V J Vis Exp; 2022 Mar; (181):. PubMed ID: 35343952 [TBL] [Abstract][Full Text] [Related]
15. Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression. Cronin-Furman EN; Borland MK; Bergquist KE; Bennett JP; Trimmer PA Mol Neurodegener; 2013 Jan; 8():6. PubMed ID: 23351342 [TBL] [Abstract][Full Text] [Related]
16. Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Esteves AR; Domingues AF; Ferreira IL; Januário C; Swerdlow RH; Oliveira CR; Cardoso SM Mitochondrion; 2008 Jun; 8(3):219-28. PubMed ID: 18495557 [TBL] [Abstract][Full Text] [Related]
18. Differential Expression of Complement Markers in Normal and AMD Transmitochondrial Cybrids. Nashine S; Chwa M; Kazemian M; Thaker K; Lu S; Nesburn A; Kuppermann BD; Kenney MC PLoS One; 2016; 11(8):e0159828. PubMed ID: 27486856 [TBL] [Abstract][Full Text] [Related]
19. Cybrid Models of Pathological Cell Processes in Different Diseases. Sazonova MA; Sinyov VV; Ryzhkova AI; Galitsyna EV; Melnichenko AA; Postnov AY; Orekhov AN; Sobenin IA Oxid Med Cell Longev; 2018; 2018():4647214. PubMed ID: 29983856 [TBL] [Abstract][Full Text] [Related]
20. A genome on shaky ground: exploring the impact of mitochondrial DNA integrity on Parkinson's disease by highlighting the use of cybrid models. Lang M; Grünewald A; Pramstaller PP; Hicks AA; Pichler I Cell Mol Life Sci; 2022 May; 79(5):283. PubMed ID: 35513611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]